US Patent No. 9,278,124

Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
Mar 11, 2016

Halozyme has been awarded US Patent No. 9,278,124, "Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods."

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

The Wall Street Journal looks into the cost of new gene therapies.

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.

Oct
11
Sponsored by
ArcherDX

This webinar will discuss a validation study for a next-generation sequencing (NGS) assay for hematological malignancies (e.g., acute myeloid leukemia, acute lymphocytic leukemia, myelodysplastic syndrome, and myeloproliferative neoplasms).